1. The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma
    Katalin Piroska Kiss et al, 2018, Leukemia & Lymphoma CrossRef
  2. Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity
    Eleonora Pozzi et al, 2022, Pharmacogenomics in Drug Discovery and Development CrossRef
  3. Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics
    Andreas A. Argyriou et al, 2017, Nature Reviews Neurology CrossRef
  4. Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
    Yuki Fujimoto et al, 2021, Cancers CrossRef
  5. Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment
    Roser Velasco et al, 2019, Journal of the Peripheral Nervous System CrossRef
  6. Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives
    Antonio Sanz-Solas et al, 2023, Journal of Personalized Medicine CrossRef